Acquisition - February 3, 2014
AstraZeneca completes acquisition of BMS diabetes share
AstraZeneca has completed the acquisition of the entirety of Bristol-Myers Squibb’s interest in the companies’ diabetes alliance. In December last year, the news about the acquisition were announced and on February 1 2014 the deal was completed. According to the agreement, AstraZeneca gets ownership of the intellectual property and global rights for the development, manufacture and […]
Drug Development Pharma - January 31, 2014
AstraZeneca joins cancer consortium
Together with DKFZ and EORTC, AstraZeneca has joined the Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine. WIN is a lobal network of academics, industries, payors and patient advocacy organizations which goal is to significantly improve survival and quality of life of cancer patients in the next three years. It was initiated in 2010 with leadership from the […]
Drug Development Pharma - January 30, 2014
AstraZeneca closes India R&D unit
The drug maker is to close its Avishkar R&D centre in Bangalore, India, and move parts of its research to Great Britain. The move that will impact 168 employees and early-stage research on tuberculosis and malaria. The decision to shut the R&D centre is said to be part of an ongoing global restructuring exercise. The pharmaceutical development […]
Agreement - January 29, 2014
FOB Synthesis enters into license agreement with AstraZeneca
FOB Synthesis has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections. The treatment will potentially combine compounds from AstraZeneca’s preclinical beta lactamase inhibitor (BLI) and FOB Synthesis’ preclinical Carbapenem antibiotic programs to help break down bacteria’s resistance to carbapenems. […]
Drug Development Pharma - January 23, 2014
EU approval for new diabetes treatment
AstraZeneca and Bristol-Myers Squibb treatment for type 2 diabetes Xigduo has been granted Marketing Authorization by the European Commission. Xigduo, which has the trade name Forxiga, combines dapagliflozin, a selective and reversible inhibitor of SGLT2 with metformin hydrochloride, two anti-hyperglycaemic products with complementary mechanisms of action to improve glycaemic control. This is the first regulatory approval for a […]
Career choice - January 15, 2014
Project Director
In his job as Project Director at AstraZeneca’s Pharmaceutical Development unit, Anders Holmén constantly has to be one step ahead and has to be able to see how science best can benefit the end customer.
